Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.

Cell reports. Medicine (2020-08-25)
Mehul S Suthar, Matthew G Zimmerman, Robert C Kauffman, Grace Mantus, Susanne L Linderman, William H Hudson, Abigail Vanderheiden, Lindsay Nyhoff, Carl W Davis, Oluwaseyi Adekunle, Maurizio Affer, Melanie Sherman, Stacian Reynolds, Hans P Verkerke, David N Alter, Jeannette Guarner, Janetta Bryksin, Michael C Horwath, Connie M Arthur, Natia Saakadze, Geoffrey H Smith, Srilatha Edupuganti, Erin M Scherer, Kieffer Hellmeister, Andrew Cheng, Juliet A Morales, Andrew S Neish, Sean R Stowell, Filipp Frank, Eric Ortlund, Evan J Anderson, Vineet D Menachery, Nadine Rouphael, Aneesh K Mehta, David S Stephens, Rafi Ahmed, John D Roback, Jens Wrammert

SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide pandemic, and there is a pressing need to understand the development, specificity, and neutralizing potency of humoral immune responses during acute infection. We report a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. RBD-specific IgG responses are detectable in all patients 6 days after PCR confirmation. Isotype switching to IgG occurs rapidly, primarily to IgG1 and IgG3. Using a clinical SARS-CoV-2 isolate, neutralizing antibody titers are detectable in all patients by 6 days after PCR confirmation and correlate with RBD-specific binding IgG titers. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.

Referencia del producto
Descripción del producto

o-Phenylenediamine, Peroxidase substrate, ≥98.0%, powder